RETRACTED ARTICLE:Nrdp1 inhibits metastasis of colorectal cancer cells by EGFR signaling-dependent MMP7 modulation

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 1129-1133

  Jiang, Yongsheng ^a   Sun, Shaochuan ^a   Liu, Guoqin ^a   Yan, Bing ^a   Niu, Jun ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; Epidermal growth factor (EGF); MMP7; Neuregulin receptor degradation protein 1 (Nrdp1)

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MATRILYSIN; NEUREGULIN RECEPTOR DEGRADATION PROTEIN 1; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB3 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; RNF41 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CACO 2 CELL LINE; CANCER INHIBITION; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYMATIC DEGRADATION; ENZYME ACTIVATION; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; PHOSPHORYLATION; TUMOR INVASION;

CACO-2 CELLS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 7; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84925515934     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2726-y     Document Type: TB

References (22)

1. East JE, Dekker E. Colorectal cancer diagnosis in 2012: a new focus for CRC prevention—more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013;10:69–70.
2. Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32.
3. Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. The development of clinical research in CRC. Ann Oncol. 2005;16 Suppl 4:iv37–43.
4. Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev. 2013;14:2201–5.
5. Qi J, Zhu YQ. Targeting the most upstream site of Wnt signaling pathway provides a strategic advantage for therapy in colorectal cancer. Curr Drug Targets. 2008;9:548–57.
6. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311–20.
7. Xu Y, Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007;16(Spec No 1):R14–20.
8. Lahm H, Odartchenko N. Role of transforming growth factor beta in colorectal cancer. Growth Factors. 1993;9:1–9.
9. Winder T, Lenz HJ. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 2010;138:2163–76.
10. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009;27:1130–6.
11. Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, et al. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One. 2013;8:e78086.
12. Ye Q, Cai W, Zheng Y, Evers BM, She QB. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2014;33:1828–39.
13. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322–7.
14. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010;6:e1001231.
15. Li LH, Zheng MH, Luo Q, Ye Q, Feng B, Lu AG, et al. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol. 2010;37:951–62.
16. Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A. 2012;109:21046–51.
17. Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res. 2006;66:11279–86.
18. Lu H, Li H, Mao D, Zhu Z, Sun H. Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27. Tumour Biol. 2014;35(9):8639–43. doi:10.1007/s13277-014-2132-5.
19. von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975;55:555–60.
20. Song H, Tian Z, Qin Y, Yao G, Fu S, Geng J. Astrocyte elevated gene-1 activates MMP9 to increase invasiveness of colorectal cancer. Tumour Biol. 2014;35:6679–85.
21. Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014; in press.
22. Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol, 2014; in press.